Ulaner et al. demonstrated that HER2-targeted PET can detect HER2-positive metastases in patients with HER2-negative primary breast cancer, meaning that HER2 PET can identify additional candidates for HER2-targeted therapy [57]. This evidence concerns the gene ERBB2 and breast carcinoma.